

AD_____

Award Number: W81XWH-04-1-0023

TITLE: MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer

PRINCIPAL INVESTIGATOR: Lili Chen, Ph.D.

CONTRACTING ORGANIZATION: Fox Chase Cancer Center
Philadelphia, PA 19111

REPORT DATE: February 2008

TYPE OF REPORT: Final Addendum

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-02-2008		2. REPORT TYPE Final Addendum		3. DATES COVERED (From - To) 1 FEB 2007 - 31 JAN 2008	
4. TITLE AND SUBTITLE MR Imaging Based Treatment Planning for Radiotherapy of Prostate Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0023	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Lili Chen, Ph.D. E-Mail: Lili.Chen@fcc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fox Chase Cancer Center Philadelphia, PA 19111				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this investigation is to develop an integrated system based on MRI simulation to improve target delineation, target localization and target motion correction for 3-dimensional conformal radiation therapy (3DCRT) and intensity-modulated radiation therapy (IMRT) of prostate cancer. We have performed studies on the effect of intra-fraction prostate motion using MR cine images and we also have been evaluating the accuracy of a stereotactic body frame for patient immobilization using MRI. We have confirmed that treatment planning dose calculations using MRI-derived homogenous geometry are adequate for patient sizes within 38 cm using the gradient distortion correction (GDC) software (Chen et al 2004a 2004b). We have quantified the residual distortions and developed computer software to reduce them using point-by-point corrections for large patients (lateral dimension up to 42 cm, (Chen et al 2006)). We have verified dosimetric accuracy and consistency for MR based IMRT treatment planning for prostate cancer using the Monte Carlo method (Chen et al 2007). We have developed a technique to create MR-based digitally reconstructed radiographs (DRR) for patient initial setup for clinical applications of MR-based treatment planning for prostate IMRT (Chen et al 2007).					
15. SUBJECT TERMS Radiotherapy, MR-based treatment planning, dosimetry, Monte Carlo dose verification, Prostate Cancer, MRI-based DRRs					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	19	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body.....	4
Key Research Accomplishments	12
Reportable Outcomes and Bibliography.....	13
Conclusions.....	17
References.....	18
List of Key Personnel.....	19

Introduction

This project is aimed at exploring MR imaging based treatment planning for radiotherapy of prostate cancer. The specific Aims include (1) to investigate the use of MRI for target delineation, target localization, patient immobilization and prostate motion studies for 3DCRT and IMRT of prostate cancer; (2) to investigate and improve the accuracy of MRI-based treatment planning dose calculation; and (3) to develop practical procedures for the clinical implementation of MRI-based treatment planning for 3DCRT and IMRT of prostate cancer. In the following we describe our work for the project.

Body

In this final report we report on the research accomplishments associated with the tasks outlined in the approved “Statement of Work” between Feb.1, 2004 and Feb. 24 2008.

Task 1. Investigation of target delineation, localization and patient immobilization using MRI

Quantification of the effect of MRI distortion on target delineation and treatment planning dose calculation

During the first year, we have focused on investigating the effect of MRI distortion on target delineation and treatment planning dose calculation. Two papers entitled “MRI-based treatment planning for radiotherapy: Dosimetric verification for prostate IMRT” and “Dosimetric evaluation of MRI-based treatment planning for prostate cancer” were published in Int. J. Radiat. Oncol. Biol. Phys. and Physics in Medicine and Biology, respectively (Chen et al 2004a, 2004b). We summarize the results and conclusions of these studies as follows.

- 1) We have studied the use of MRI-based treatment planning for prostate cancer and to verify the dosimetry accuracy of its clinical implementation using a commercial treatment planning system. The AcQPlan system Version 5 was used for the study, which is capable of performing dose calculation on both CT and MRI. A four field 3D conformal planning technique was used for the study. First, we verified the dosimetry accuracy of using homogeneous geometry for prostate planning. This was done by calculating dose distributions using the distortion-free CT data with and without heterogeneity correction (equivalent TAR), respectively. As a result, two treatment plans were generated for each patient with the same treatment parameters (i.e., energy, gantry angle, block shape and size, and dose prescription). Second, we evaluated the dosimetry accuracy between CT-based and MRI-based dose calculation. This was achieved by calculating dose distributions using both CT and MRI data without heterogeneity correction (i.e., using homogeneous geometry defined by the patient external contour). The same MUs obtained from CT-based plans were directly used in MRI-based plans so that the effects of residual MRI distortions on external contours and the differences in internal structure volumes between CT and MRI can be quantified. The plans were evaluated based on isodose distributions and dose volume histograms (DVHs) for the target and the critical structures. Based on the DVHs, doses were reported at 95% of the planned treatment volume (PTV), D95, for the prostate, at 35% (D35) and 17% (D17) of the rectum volume, and at 50% (D50) and 25% (D25) of the bladder volume. These dose points were chosen based on our current clinical acceptance criteria for prostate cancer treatments. Our results confirmed that treatment planning

dose calculations using MRI-derived homogenous geometry are adequate for patient sizes within 38 cm after MR image distortion is corrected using the GDC software (Chen et al 2004b).

- 2) We have investigated the effect of MRI residual distortion after GDC on IMRT treatment planning and dosimetry accuracy. Our results showed that the residual distortion errors are less than 1 cm and will have a negligible clinical impact for more than 90% of the prostate patients whose lateral dimensions are < 40 cm (Chen et al 2004a).
- 3) We also studied structure volume differences between CT and MRI on the AcQSim and Corvus systems, which led to small discrepancies in DVH curves for those structures with significant differences. These differences reflected the inherent uncertainties of target and structure delineation using different imaging modalities and different treatment planning systems. However, these DVH discrepancies will not be a problem when MRI is used alone for treatment planning since both structure contouring and treatment optimization will be performed using the same imaging modality (Chen et al 2004a, 2004b).
- 4) We evaluated MRI- and CT-based IMRT treatment optimization for plan consistency. Since both planning techniques will be used clinically and in different treatment protocols it is essential to ensure IMRT plans using both imaging modalities are consistent in terms of target coverage, dose conformity and normal tissue sparing. Our results showed that no clinically significant differences were found between MRI- and CT-based treatment plans using the same beam arrangements, dose constraints and optimization parameters (Chen et al 2004b).
- 5) We validated the dosimetry accuracy of MRI-based treatment planning by recomputing MRI-based IMRT plans using patient CT data and an IMRT QA phantom. The differences in dose distributions between MRI plans and the corresponding recomputed plans were generally within 3%/3mm. The differences in isocenter doses between MRI dose calculation and phantom measurements were within our clinical criterion of 4% (Chen et al 2004a).

Validation and improvement of gradient distortion correction for MRI-based treatment planning

The goal of our study is to provide “correct” pelvic images in which geometrical distortions are reduced to < 2 mm for target delineation and < 5 mm for external contour determination (which will be used to define patient geometry for dose calculation). This will require an assessment of the sources and magnitudes of the different contributions to distortions in images acquired using our 0.23 T MRI unit. In order to achieve the goal, first we quantified the residual distortions for 15 patients. The residual error was within 1 cm for patients with lateral dimensions < 40 cm. The values determined this way should have included the residual MRI distortions (both system related and object induced), differences in external contours due to patient setup between CT and MRI simulation, and the errors introduced by image fusion, which was estimated to be at the 2-3 mm level, which was achieved routinely in our clinic. The object induced effects are a result of both chemical shift and susceptibility effects due to the differences in the resonant frequency between fat and water and the magnetic field distortions introduced at tissue-air interfaces. The chemical shift artifacts and susceptibility distortion are larger on high-field MR units than on lower-field MR units. While chemical shift artifacts and susceptibility distortion can cause significant spatial misregistrations at high fields, their impact on

MRI at lower fields is substantially reduced. For fields below about 0.5 Tesla (T), imaging sequences that provide a sufficient signal to noise ratio keep geometric distortion due to either of these object-related effects below 1-2 pixels. This is achieved by defining a lower limit for the bandwidth of the readout gradient during image acquisition. One in vivo study has shown that with 0.2 T using a bandwidth readout gradient >100 Hz/pixel in frequency direction there is no artifact detected (Fransson et al 2001). In our clinical routine MR simulation we have chosen 154 Hz/pixel in the frequency encoding direction, therefore the effects caused by chemical and susceptibility are considered negligible. In this study we aimed on correction of the residual distortion after GDC correction due to system induced distortion. We performed phantom measurements to calibrate/quantify MRI distortion at different axial planes to derive distortion maps for phantom of different sizes. We have compared these maps with the measured distortion using real patients by comparisons with CT images. A point-by-point mapping technique was developed and computer software for improving the residual distortion using this method was also generated. Our results showed that by using this technique the residual distortion can be reduced to < 3 mm for patient lateral sizes up to 42 cm. A paper entitled "Investigation of MR Image Distortion for Radiotherapy Treatment Planning of Prostate Cancer" was published in Phys. Med. Biol (Chen et al 2006).

Investigation of the accuracy of a stereotactic body frame for patient immobilization

We performed MRI for different target localization and patient immobilization techniques to quantify the effect of prostate motion, and then to determine special treatment margins correspondingly. These will include alpha-cradle alone, and a stereotactic body frame from Radionics (Boston, MA). A Radionics Body Frame localizing system has been investigated at FCCC for accurate immobilization of patients undergoing stereotactic radiosurgery/therapy (SRS/SRT) using stereotactic IMRT optimization software and a micro multileaf collimator (mMLC) (Wang et al 2004a, 2004b).

The body system is a whole body fixation system using airflow modules, a vacuum system and fixation sheets. The treatment area is covered with a fixation sheet. When the vacuum system is turned on, the space around the patient between the vacuum cushion and the sheet is evacuated and the sheet is sucked against the vacuum cushion. The sheet nestles against the patient's body producing a uniform fixation to the body surface without causing impression.

To study the patient immobilization and target localization accuracy for this body system, we used the 0.23 T MRI to collect sequential axial and sagittal images of prostate patients. Each patient underwent one scan per week for 4 weeks. For this study, a fast image is required. The temporal resolution requires shorter than the breathing cycle (approximately 2.5 s) to measure respiration-related motion. We scanned the patients in both axial and sagittal planes respectively. T1 weighted FSE images with cines at 3 mm slice thickness with 60 images obtained every 2 seconds ($TR/TE = 18/8$ ms, $FOV = 475$ mm, $Matrix = 128 \times 256$, $ETL = 1$, scan time 2 s) were obtained based on our pilot experiment. The prostate replacement was measured on MRI console in three dimensions on both axial and sagittal images and the absolute values of the displacement calculated based on pixel value. This experimental procedure was repeated without the vacuum body frame. The replacement of the prostate was compared between with and without the body frame. This can help us quantify the improvement with the body frame.

Task 2. Investigation of MRI-based treatment planning dose calculation

Evaluation of MRI-based prostate treatment planning dose calculation

We have focused on MR image distortion correction to further improve the accuracy of dose calculation for MR based treatment planning for prostate cancer (Chen et al 2006). We also used the Monte Carlo method to verify dosimetric accuracy and consistency for MR based IMRT treatment planning for prostate cancer (Chen et al 2007a). We summarize the results and conclusions of these studies as follows.

- (1) We have focused on MR image distortion correction to further improve the accuracy of dose calculation for MR based treatment planning for prostate cancer. Our studies showed that, with our routine clinical 3-dimensional fast spin echo sequences (3DFSE, 256 x 256, 1.855 mm pixel, TR = 140 ms, TE = 3000 ms, BW readout gradient > 100 Hz/pixel), there was no patient-induced distortions. Therefore, the residual machine specific geometrical distortions after the gradient distortion correction (GDC) could be quantified by phantom measurements and further reduced by our point-by-point correction technique. The effective field of views (FOV_{eff}) of the scanner were established based on the actual viewable areas with adequate geometric distortion corrections (ensuring < 5 mm distortion error). The effective FOV_{eff} for prostate imaging using a standard FOV of 48 cm has been expanded from 36 cm using the existing GDC software to 42 cm using the point-by-point distortion correction technique developed in this work. Our results indicated that, with the distortion maps established in this work, we could correct MR geometrical distortions for patients of lateral dimensions up to 42 cm. Significant improvement in dose calculation has been achieved based on a 1-2 cm improvement in patient external contour determination.
- (2) We have performed the Monte Carlo method to verify dosimetric accuracy and consistency for MR based IMRT treatment planning for prostate cancer. The Monte Carlo code used in this work was MCSIM, which is an EGS4/PRESTA user code developed at Fox Chase Cancer Center (FCCC) (Ma et al 2002). The beam information was represented using a source model, which was built based on measured beam data (Jiang et al 2000, 2001; Yang et al 2004), and validated for Monte Carlo dose calculation for photon beams from our Siemens accelerators. During the calculation, the multi-leaf collimator leakage effect was taken into account when intensity maps were reconstructed from a plan. The accuracy of the dose calculation was better than 2% compared with measured data (Li et al 2000). For each patient, an RTP file from the Corvus treatment planning system that includes patient setup parameters and beam and leaf-sequence information was used for the Monte Carlo dose calculation. For the Monte Carlo simulation, the electron and photon energy cutoffs, ECUT and PCUT, for particle transport were set to 700 keV and 10 keV, respectively. The energy thresholds for δ ray production (AE) and for Bremsstrahlung production (AP) were also set to 700 keV and 10 keV, respectively. The maximum fractional energy loss per electron step (ESTEP) was set to 0.04 and the default parameters were used for the PRESTA algorithm. The patient geometry used for the Monte Carlo calculations was created based on both CT and MR data. The materials and mass densities of CT based geometries were converted from the CT numbers based on a piecewise linear conversion curve that was given by Ma et al (1999). Seventy million particle histories were used in the Monte Carlo simulations to achieve less than 0.5% statistical uncertainties to

the target dose for all the IMRT plans. Each photon was split 20 times to improve the simulation efficiency using the photon-splitting technique implemented in MCSIM.

- (3) We have performed CT-based IMRT Monte Carlo dose calculations with and without heterogeneity corrections in order to investigate the heterogeneity effect caused by different beam angle arrangements. Based on the results, MR-based IMRT dose calculations were performed using either uniform density geometry or uniform density geometry with bulk electron density assigned to bony structures. For the plans with insignificant inhomogeneity effect, uniform geometries with water density were used in the MR-based dose calculation. For the plans that bony structure constitutes a large part of volume irradiated, uniform density geometry with bulk electron density assigned to bony structures was used in the MR-based dose calculation. Each IMRT plan was evaluated based on isodose distributions and dose volume histograms (DVHs) with CT-based or MR-based dose calculations. The clinical target volume (CTV) was chosen for the dose-volume comparison. Clinical quantities such as the mean dose, maximum and minimum dose received by the CTV and the critical structures were compared. The maximum dose was defined as the highest dose received by 1% of the target volume and the minimum dose was defined as the lowest dose received by 99% of the target volume, respectively. Other parameters such as the dose at the isocenter and the dose received by 95% and 5% of the CTV were also compared. The paired CT and MR data for any patients in this work were pre-processed to have the same pixel resolution. The internal contours of the targets and critical organs were contoured by oncologists on the fused CT-MR images. A special computer code was developed to convert the patient CT and MR image data from the DICOM format to geometries specially formatted for the MCSIM code.

Development of practical methods for heterogeneity correction for MRI-based dose calculation

Our preliminary results demonstrated that MR-based planning was equally good as CT-based planning for prostate cancer with homogeneity geometry in the dose calculation. The differences between CT and MR-based dose calculations came from the setup uncertainties in the CT and MR image acquisition (Chen et al 2005). For prostate cancer, the following beam arrangements were commonly used for routine treatment IMRT plans at Fox Chase Cancer Center: 1) one anterior, 2) two or four anterior oblique, 3) two lateral and 4) two or four posterior oblique beams. The couch angles were set as zero (i.e. coplanar beam arrangements). Our results showed insignificant differences in the clinical quantities between MR-based dose calculations with uniform water equivalent geometry and CT-based dose calculations with heterogeneity correction. The maximum differences were less than 4% and the averaged differences over the 10 IMRT plans were less than 1.6% for all the quantities in the comparison, indicating that the uniform geometry was a good approach with our commonly used beam arrangements. These results were consistent with previous findings (Chen et al 2004 and Yang et al 2004).

However, for some clinical cases non-coplanar beam arrangements were needed to achieve better target dose coverage and rectal sparing. Our results showed that with non-coplanar beam arrangements more than 10% differences between plans with and without heterogeneity correction were found in the single beam calculations for the beam going through a large amount of pelvic bones. To utilize MR-based planning for the treatment with large amount of pelvic bones irradiated, heterogeneity corrections must be taking into account and a bulk-density can be assigned to bony structures as proposed by this project since there is no point-to-point correlation between MR signal intensities and

electron densities of the materials imaged (Lee and Bollet 2003, Chen et al 2004b). Various bulk-densities (between 1.5 and 2.2 g/cm³) were assigned to the femurs and femoral heads in this work. Our results showed that 1.8g/cm³ is the optimal value for the bulk-density assignment.

For those beams with gantry/table angles as 275/340, 85/20 and 85/0, the differences in the average target doses were decreased from about 10% with uniform water equivalent geometry to about 3% or less after assigning 1.8g/cm³ bulk density to femurs and femoral heads. The changes in DVHs using CT data with 1.8g/cm³ bulk density for the femurs and femoral heads also confirmed our findings.

Task 3. Development of practical procedures for clinical implementation of MRI simulation

Creation of MR-based Digitally Reconstructed Radiographs (DRRs)

We have focused on developing a technique to create MR-based digitally reconstructed radiographs (DRR) for prostate IMRT patient setup when MR-based treatment planning is applied clinically. A paper entitled “MRI-Based Treatment Planning for Prostate IMRT: Creation of Digitally Reconstructed Radiographs (DRR)” was published in *Int. J. Radiat. Oncol. Biol. Phys* (Chen et al 2007b). We studied MR image distortion corrections to further improve the accuracy of dose calculation for MR based treatment planning for prostate cancer. A paper entitled “Investigation of MR image distortion for radiotherapy treatment planning of prostate cancer” has been published in *Physics in Medicine and Biology* (Chen et al 2006). We also used the Monte Carlo method to further verify dosimetric accuracy and consistency for MR based IMRT treatment planning for prostate cancer. A short paper entitled “Monte Carlo dose verification of MR image based IMRT treatment planning for prostate cancer” has been submitted to XVth International Conference on the Use of Computers in Radiation Therapy (ICCR, Toronto, Jun 2007) (Chen et al 2007b). The two manuscripts together with the published paper are also attached to this report. We summarize the results and conclusions of these studies as follows.

Our previous studies demonstrated that MRI-based treatment planning meets the dosimetric accuracy for prostate IMRT and it is adequate to use unity density in treatment planning dose calculation with co-planar beam arrangements for prostate cancer treatment after correction of MRI distortions (Chen et al 2004a, 2004b). With CT-based treatment planning, the CT-based DRRs are routinely used for patient treatment set-up verification by comparing with portal film or electronic portal imaging devices (EPID). With MR-based treatment planning, Since MRI-derived DRRs do not provide enough bony structure information and therefore cannot be used directly for checking patient positions. To overcome this problem, we have developed a technique to create MR-based DRRs for patient initial setup for routine clinical applications of MR-based treatment planning for prostate patient treated with IMRT. Twenty prostate patients' CT and MR images were used for the study. CT and MR images were fused. The pelvic bony structures including femoral heads, pubic rami, ischium and ischial tuberosity that are relevant for routine clinical patient setup were manually contoured on axial MR images using the AcQsim planning system. The contoured bony structures were then assigned a bulk density of 2.0 g/cm³. The MRI based DRRs were generated. The accuracy of the MR based DRRs was quantitatively evaluated by comparing MR-based DRRs with CT-based DRRs for these patients. For each patient 8 measuring points on both coronal and sagittal DRRs were used for quantitative evaluation. Our results showed that the maximum difference in the mean values of these measurement points is 1.3 and the maximum difference in absolute positions is within 3 mm for the 20 patients investigated. MR-based DRRs are comparable to CT-based DRRs for prostate IMRT. This technique

has been used, in combination with the BAT/in-room CT daily target localization technique, for the clinical implementation of MRI-based treatment planning for prostate IMRT at FCCC.

Development of guidelines for MRI-based treatment planning dose calculation

We investigated the effect of MRI residual distortion after gradient distortion correction (GDC) on IMRT treatment planning and dosimetry accuracy. The residual distortion errors are less than 1 cm and will have negligible clinical impact for more than 90% of the prostate patients whose lateral dimensions are <40 cm. We have investigated on MR image distortion correction to further improve the accuracy of dose calculation for MR based treatment planning for prostate cancer. Our studies showed that, with our routine clinical 3-dimensional fast spin echo sequences (3DFSE, 256 x 256, 1.855 mm pixel, TR = 140 ms, TE = 3000 ms, BW readout gradient > 100 Hz/pixel), there was no patient-induced susceptibility distortions. Therefore, the residual machine specific geometrical distortions after the GDC could be quantified by phantom measurements and further reduced by our point-by-point correction technique. The effective field of view (FOV_{eff}) of the scanner was established based on the actual viewable areas with adequate geometric distortion corrections (ensuring < 5 mm distortion error). The effective FOV_{eff} for prostate imaging using a standard FOV of 48 cm has been expanded from 36 cm using the existing GDC software to 42 cm using the point-by-point distortion correction technique developed in this work. Our results indicated that, with the distortion maps established in this work, we could correct MR geometrical distortions for patients of lateral dimensions up to 42 cm. Significant improvement in dose calculation has been achieved based on a 1-2 cm improvement in patient external contour determination (Chen et al 2006).

Our previous study results showed that no clinically significant differences in dose calculations were found between MRI- and CT-based treatment plans using the same beam arrangements, dose constraints and optimization parameters. We also validated the dosimetry accuracy of MRI-based treatment planning by recomputing MRI-based IMRT plans using patient CT data and an IMRT QA phantom. The differences in dose distributions between MRI plans and the corresponding recomputed plans were generally within 3%/3mm. The differences in isocenter doses between MRI dose calculation and phantom measurements were within our clinical criterion of 4%.

This year we focused on the Monte Carlo method to further verify dosimetric accuracy and consistency for MR based IMRT treatment planning for prostate cancer. The Monte Carlo code used in this work was MCSIM, which is an EGS4/PRESTA user code developed at FCCC (Ma et al 2002). We have performed CT-based IMRT Monte Carlo dose calculations with and without heterogeneity corrections in order to investigate the heterogeneity effect caused by different beam angle arrangements. Based on the results, MR-based IMRT dose calculations were performed using either uniform density geometry or uniform density geometry with bulk electron density assigned to bony structures. For the plans with insignificant inhomogeneity effect, uniform geometries with water density were used in the MR-based dose calculation. For the plans that bony structure constitutes a large part of volume irradiated, uniform density geometry with bulk electron density assigned to bony structures was used in the MR-based dose calculation. Each IMRT plan was evaluated based on isodose distributions and dose volume histograms (DVHs) with CT-based or MR-based dose calculations. The clinical target volume (CTV) was chosen for the dose-volume comparison. Clinical quantities such as the mean dose, maximum and minimum dose received by the CTV and the critical structures were compared. The maximum dose was defined as the highest dose received by 1% of the target volume and the minimum dose was defined as the lowest dose received by 99% of the target volume, respectively. Other parameters such

as the dose at the isocenter and the dose received by 95% and 5% of the CTV were also compared. The paired CT and MR data for any patients in this work were pre-processed to have the same pixel resolution. The internal contours of the targets and critical organs were contoured by oncologists on the fused CT-MR images. A special computer code was developed to convert the patient CT and MR image data from the DICOM format to geometries specially formatted for the MCSIM code (Chen et al 2007).

Our results showed that the differences in dose calculations between CT data (with heterogeneity correction) and MR data (with uniform water equivalent geometry) were about 3% or less and less than 2% in the mean values for the 10 plans with beams arranged in the axial plane. For MR-based calculations (with homogeneous geometry), our results demonstrated that the differences between MR-based calculations and CT-based calculations (without heterogeneity correction) were less than 2% for the individual patients and about 1% in the mean values, which proved that MR-based IMRT plans can be used to replace CT-based planning clinically. The 1% - 2% differences in dose calculations were mainly caused by the setup uncertainties of the two imaging modalities if geometrical distortions on the MR images were corrected to less than 3 mm. For treatments in which relatively large amount of bones are irradiated, MR-based treatment planning with homogeneous geometry would not be appropriate because of the excessive attenuation of the photon beams passing through bony structures. However, by assigning bulk densities to the bony structures especially for the femurs and femoral heads, the dose differences could be reduced to less than 3%. The bulk density assigned to the femurs that gave the best fits to CT-based calculations with heterogeneity correction was 1.8g/cm^3 in our simulations (Chen et al 2007).

Development of quality assurance programs for MRI simulation for prostate cancer treatment

We have established a practical procedure for MR-based treatment planning. 1) An optimal MR protocol was first developed for contouring the target and critical structures. 2) We investigated the effect of MRI residual distortion after the GDC on IMRT treatment planning and dosimetry accuracy. The residual distortion errors are less than 1 cm and will have negligible clinical impact for more than 90% of the prostate patients whose lateral dimensions are <40 cm. For patients whose lateral dimensions are >40 cm we will use the point-by-point distortion correction technique developed in this work. Our results indicated that, with the distortion maps established in this work, we could correct MR geometrical distortions for patients of lateral dimensions up to 42 cm. 3) We have investigated optimal fiducial markers for MRI simulation. We have introduced a new donut-shaped marker to improve isocenter definition (IZI medical Product, Baltimore, Maryland 21244). The marker contains iodine with a 1.5 cm outer diameter and a 4 mm inner diameter. The centers of the markers can be detected clearly on one MR slice to define the treatment isocenter. To implement MRI simulation, a set of trackable lasers has been installed in the MR room for patient setup and isocenter determination. 4) We have demonstrated that MRI-based treatment planning meets the dosimetric accuracy for prostate IMRT and it is adequate to use unity density in treatment planning dose calculation with co-planar beams for prostate cancer treatment after MRI distortion corrections (Chen et al 2004a, 2004b). 5) We have developed practical methods for heterogeneity correction for MRI-based dose calculations (Chen et al 2007). 6) finally MRI-based DRRs are used during initial treatment setup together with CT-on-rails/cone-beam CT/BAT and later on as a backup for these imaging systems if the systems are down. We investigated the creation of MRI-based DRRs to facilitate initial patient setup. CT-based DRRs are routinely used for patient treatment setup verification by comparing with portal film or electronic portal imaging devices (EPID). However, directly MRI-derived DRRs do not provide enough bony

structure information and therefore cannot be used directly for checking patient positions. To overcome this problem, a practical method to derive MRI-based DRRs for IMRT prostate patient setup has been developed. The relevant bony structures on MRI including pubic symphysis, femoral heads and acetabulum are contoured and assigned a bulk density of 2.0 g/cm^3 . The bony structures are then clearly shown on the MRI-derived DRRs and can be used for patient treatment setup verification. The accuracy of this method has been verified by comparing with CT derived DRRs and the agreement between the two methods are estimated to be 2-3 mm based on 20 patients investigated (Chen et al 2007).

Key Research Accomplishments

We have accomplished the following tasks:

- We have verified the dosimetry accuracy of prostate treatment planning using homogeneous patient geometry by doing dose calculations on CT with and without heterogeneity correction for 15 patients.
- We have evaluated the dosimetric accuracy of CT- and MRI-based treatment planning using homogeneous geometry using AcQSim planning system.
- We have investigated the effect of MRI residual distortion after GDC on IMRT treatment planning and dosimetry accuracy.
- We have studied structure volume differences between CT and MRI on the AcQSim and Corvus system.
- We have evaluated MRI- and CT-based IMRT treatment optimization for plan consistency.
- We have validated the dosimetry accuracy of MRI-based treatment planning by recomputing MRI-based IMRT plans using patient CT data and an IMRT QA phantom.
- We have developed a point-by point distortion correction technique to correct MR geometrical residual distortions with the use of the gradient distortion correction (GDC) software.
- We have developed practical methods for heterogeneity correction for MRI-based dose calculation in inhomogeneous patient anatomy.
- We have used the Monte Carlo method to validate the dose accuracy and consistency for MR-based treatment planning of prostate cancer.
- The dose accuracy for MR-based treatment planning of prostate cancer has been validated using the Monte Carlo method and demonstrated consistent results.
- A practical method for heterogeneity correction for MRI-based dose calculation in inhomogeneous patient anatomy has been developed.

- A practical technique to create MR-based DRRs for prostate IMRT has been developed that can be used for patient setup when MR-based treatment planning is applied clinically.

Reportable Outcomes and Bibliography

Peer-reviewed papers resulting from or supported in part by this grant:

1. **Chen L**, Price RA Jr., Wang L, Li JS, Qin L, Ding M, Palacio E, T-B Nguyen, Ma C-M, Pollack A. Dosimetric evaluation of MRI-based treatment planning for prostate cancer. *Phys. Med. Biol.* 49: 5157-5170 (2004a).
2. **Chen L**, Price RA Jr., Wang L, Li JS, Qin L, Shawn M, Ma C-M, Freedman GM and Pollack A. MRI-Based Treatment Planning for Radiotherapy: Dosimetric Verification for Prostate IMRT. *International Journal of Radiation Oncology Biology Physics* 60(2): 636-47 (2004b).
3. **Chen L**, Li JS, Price RA et al. Investigation of MR-Based Treatment Planning for Lung and Head & Neck using Monte Carlo Simulations *The XIVth Internatinal Conference on the use of Computers in Radiation Therapy* 520-523, (2004c).
4. Li JS, Freedman GM, Price R, Wang L, Anderson P, **Chen L**, Xiong W, Yang J, Pollack A and Ma C-M. Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer. *Med. Phys.* 31 (5), 1023-1031 (2004).
5. Ma CM, Price RA Jr. Li JS, **Chen L**, Wang L, Fourkal E, Qin L and Yung J. Monitor unit calculation for Monte Carlo treatment planning. *Phys. Med. Biol.* 49 1671-1687 (2004).
6. Ma, C.M, Li, J.S, Pawlicki, T, Jiang, S.B, Deng, J, Price, R.A. **Chen, L**, Wang, L, Fourkal, E, Qin, L.H., Yang, J, Xiong, W. MCSIM - A Monte Carlo Dose Calculation Tool for Radiation Therapy. *Proc. of the XVIth International Conference on the Use of Computer in Radiation Therapy* (ICCR, Seoul, 2004) pp515-9.
7. Qin, L, Li, J.S, Price, R.A, **Chen, L**, McNeeley, S, Ding, M, Fourkal, E, Freedman, G, Ma, C.M. A Monte Carlo Based Treatment Optimization Tool for Modulated Electron Radiation Therapy. *Proc. of the XIVth International Conference on the Use of Computer in Radiation Therapy* (ICCR, Seoul, 2004) pp527-30.
8. Qin, L, **Chen, L**, Li, J.S, Price, R.A, Yang, J, Xiong, W, Ma, C.M. Phase Space Analysis of Siemens Electron Beams for Monte Carlo Treatment Planning. *Proc. of the XIVth International Conference on the Use of Computer in Radiation Therapy* (ICCR, Seoul, 2004) pp665-8.
9. Xiong W, Li J, **Chen L**, Price RA, Freedman G, Ding M, Qin L, Yang J and Ma C-M. Optimization of combined electron and photon beams for breast cancer. *Phys. Med. Biol.* 49 1973-1989 (2004).
10. Wang L, R Jacob, **Chen L**, Feigenberg S, Konski A, Ma C and B Movsas. Stereotactic IMRT for prostate cancer: Setup accuracy of a new stereotactic body localization system. *Journal of Applied Clinical Medical Physics* 5: 18-28 (2004a).
11. Wang L, Movsas B, Jacob R, Fourkal E, **Chen L**, Price R, Feigenberg S, Konski A, Pollack A and Ma C. Stereotactic IMRT for prostate cancer: Dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT. *Journal of Applied Clinical Medical Physics* 5: 29-41 (2004b).

12. Wang L, Hoban P, Paskalev K, Yang J, Li J, **Chen L**, Xiong W, Ma CM. Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity-modulated radiotherapy *Medical Dosimetry* 30 (2): 97-103 (2005).
13. Yuh EL, Shulman SG, Mehta SA, Xie J, **Chen L**, Frenkel V, Bednarski MD and Li KCP. Delivery of a Systemic Chemotherapeutic Agent to Tumors Using Focused Ultrasound: study in a murine model *Radiology* February 1, 2005; 234(2): 431 - 437.
14. Yang J, Li J, **Chen, L**, Price RA, McNeeley S, Qin L, Wang, L, Xiong W and Ma C-M. Monte Carlo evaluation of heterogeneity effect in IMRT treatment planning for prostate cancer *Phys. Med. Biol.* 50: 1-10 (2005).
15. Yang J, Li J, **Chen L**, Price R, McNeeley S, Qin L, Wang L, Xiong W, Ma C-M. Dosimetric verification of IMRT treatment planning using Monte Carlo simulations for prostate cancer. *Phys Med Biol.* 50(5): 869-78 (2005).
16. Chen Z, Ma C-M, Paskalev K, Li J, Yang J, Richardson T, Palacio L, Xu X and **Chen L**. Investigation of MR Image Distortion for Radiotherapy Treatment Planning of Prostate Cancer. *Phys. Med. Biol* 51 1393-1403 (2006).
17. Luo W, Li J, Price RA Jr, Chen L, Yang J, Fan J, Chen Z, McNeeley S, Xu X, Ma CM. Monte Carlo based IMRT dose verification using MLC log file and R/V outputs. *Med. Phys.* 33 (7): 2557-64 2006.
18. Fan J, Li J, **Chen L**, Stathakis S, Luo W, Du Plessis F, Xiong W, Yang J, Ma CM. A practical Monte Carlo MU verification tool for IMRT quality assurance. *Phys Med Biol* 21;51(10):2503-15 2006.
19. Wang L, Li J, Paskalev K, Hoban P, Luo W, **Chen L**, McNeeley S, Price R, Ma C. Commissioning and quality assurance of a commercial stereotactic treatment-planning system for extracranial IMRT. *Journal of Applied Clinical Medical Physics* 7: 21-34 (2006).
20. Wang L, Feigenberg S, **Chen L**, Paskalev K and C-M Ma. Benefit of three-dimensional image-guided stereotactic localization in the hypofractionated treatment of lung cancer. *International Journal of Radiation Oncology Biology Physics* 66 (3): 738 – 747 (2006).
21. Breen Michael, Breen Miyuki, Butts K, **Chen L**, Sidel GM, Wilson DL. MRI guided thermal ablation therapy: model and parameter estimates to predict cell death from MR thermometry images. *Annals of Biomedical Engineering* 35 (8) 1391-1403 (2007).
22. Chen Z, Ma C-M, Yang J, Li J, Luo W, Fan J, Paskalev KA, A. Price Jr., A Chen Y and **Chen L**, Monte Carlo dose verification of MR image based IMRT treatment planning for prostate cancer, Proc. of the 15th International Conference on the Use of Computer in Radiation Therapy (ICCR), Eds: Jean-Pierre Bissonnette (Novel Digital Publishing, Oakville), Volume II: 267-71 (2007a).
23. **Chen L**, Nguyen T-B, Jones E, Chen Z, Luo W, Wang L, Price RA, Pollack A and Ma C-M. MRI-Based Treatment Planning for Prostate IMRT: Creation of Digitally Reconstructed Radiographs (DRR). *International Journal of Radiation Oncology Biology Physics* 68;(3): 903-11 (2007b).

Non peer-reviewed papers resulting from or supported in part by this grant:

- **Chen L**. Magnetic resonance has proven useful in radiation therapy simulation and treatment planning for prostate intensity-modulated radiation therapy *Advance for Imaging and Oncology* 14 57-58 (2004).

Book Chapter

- Y. Cao and **L. Chen**. MRI in Radiation Treatment Planning and Assessment. In: Integrating New Technologies into the Clinic: Monte Carlo and Image-Guided Radiation Therapy (ed. Bruce H. Curran, James M. Balter, and Indrin J. Chetty). Medical Physics Publishing (Madison, WI), 2006, pp401-424.

Meeting abstracts resulting from or supported in part by this grant:

1. **Chen L**. Cancer treatment with MRI-guided high intensity focused ultrasound. Medical Physics, 2007; 34: 2588.
2. **Chen L**, Hachem P, Hananel A, Mu Z, Padovani L, Mercier C, Khor L, Kwon H, Ma C, and Pollack A. MR guided focused ultrasound (MRgFU) for the treatment of prostate cancer: A feasibility study of increasing cellular uptake of AS-MDM2 in vivo. Medical Physics, 2007; 34: 2625.
3. **Chen L**, Xu X, Zhu J, Chen Z, Richardson T, Feigenberg S, Wang L, Price R, and **Ma C**. MRI-based treatment planning for glioblastoma (GBM): Dosimetric validation. Medical Physics, 2007; 34: 2473-2473.
4. Fan J, Li J, **Chen L**, Price R, Paskalev K, Chen Z, Stathakis S, Luo W, Ma C. Generic source models for commonly used clinical accelerator beams for Monte Carlo treatment planning. Medical Physics, 2006; 33: 2292.
5. Ma C, Li J, Stathakis S, Leal A, DuPlessis F, Fan J, Chen Y, **Chen L**, McNeeley S and Price R. Advanced mixed beam radiotherapy for breast and head and neck. Medical Physics, 2006; 33: 2256-2257.
6. Luo W, Li J, Price R, **Chen L**, Fan J, Chen Z, Lin T, Wang L and Ma C. Developing a comprehensive patient-specific QA procedure for IMRT. Medical Physics, 2006; 33: 2247-2248.
7. **Chen L**, Paskalev K, Xu X, Zhu J, Wang L, Price R, Horwitz E, Feigenberg S, Pollack A and Ma C. Rectal dose variation in image guided radiation therapy of prostate cancer. Medical Physics, 2006; 33: 2189.
8. Chen Z, Ma C, Li J, Paskalev K, price R, Luo W, Fan J, Chen Y, Lin T and **Chen L**. Monte Carlo investigation of dose perturbation by hip replacements in intensity modulated radiotherapy of prostate cancer. Medical Physics, 2006; 33: 2122.
9. Wang L, Feigenberg S, **Chen L**, Paskalev K, Jin L and Ma C. How to account for patient-specific tumor motion in target definition for lung cancer treatment planning: dosimetric comparison of a multi-phase CT simulation approach and MRI cine study. Medical Physics, 2006; 33: 2037.
10. Wang L, Feigenberg S, Paskalev K, Chen L and Ma C. Benefit of 3D image-guided stereotactic localization in the hypofractionated treatment of lung cancer. Medical Physics, 2006; 33: 1993
11. Chen Z, Ma C, Li J, Paskalev K, Price R, Luo W, Fan J, Stathakis S, Chen Y, Lin T and Chen L. Effect of voxel size on Monte Carlo dose calculation for intensity modulated radiotherapy treatment planning. Medical Physics, 2006; 33: 2095.
12. **Chen L**, Paskalev K, Zhu J, Xu X, Wang L, JR, Price R.A, Horwit E, Feigenberg S, Ma C.C and Pollack A. Image Guided Radiation Therapy for Prostate IMRT: Rectum Volume Changes and Dosimetric Considerations. *International Journal of Radiation Oncology Biology Physics*, **63** (ASTRO 2005): 549-550.
13. Breen MS, Butts K, **Chen L**, Saidel GM, Wilson DL. Laser Thermal Ablation: Model and Parameter Estimates to Predict Cell Death from MR Thermometry Images. 13th Scientific

Meeting of the International Society for Magnetic Resonance in Medicine. Miami, Florida, May 2005.

14. **Chen L**, Zhu J, Xu x, Wand L, Paskalev K, Chen Z, Movsas B, Ma C. Image guided radiation therapy: investigation of interfraction setup and external contour variation for prostate IMRT using CT and MRI. *Proc. Medical Physics*, 32(6), 1928, 2005.
15. Fan J, Li J, **Chen L**, Xiong W, Stathakis S, Luo W Plessis F Du Ma C. A practical Monte Carlo MU verification tool for IMRT quality assurance *Proc. Medical Physics*, 32(6), 1979, 2005.
16. Ma C, Li J, Price R, **Chen L**, Konski A, Watlins-Bruner D, Pollack A. Treatment optimization for prostate IMRT incorporating utility analysis and patient decisions. *Proc. Medical Physics*, 32(6), 2039, 2005.
17. Chen Z, Yang J, Li J, Paskalev K, Ma C, **Chen L**. Monte Carlo dose verification for MRI-based treatment planning of prostate cancer. *Proc. Medical Physics*, 32(6), 1884, 2005.
18. Yang J, Li J, **Chen L**, Chen Z, Luo W, Fan J, Stathakis S, Price R, Ma C. Mote Carlo investigation of heterogeneity effect for head and neck IMRT. *Proc. Medical Physics*, 32(6), 1886, 2005.
19. **Chen L**, Paskalev K, Zhu J, Xu X, Wang L, Price R, Horwitz E, Feigenberg S, Pollack A, Ma C. Image Guided Radiation Therapy for Prostate IMRT: Rectum Volume Changes and Dosimetric Considerations. *Proc. International Journal of Radiation Oncology Biology Physics* 2005.
20. Breen MS, Butts K, **Chen L**, Saidel GM, Wilson DL. Image-guided Laser Ablation: Model to Predict Cell Death from MR Temperature Images. *2nd Annual Case Western Reserve University Research ShowCASE*. Cleveland, Ohio, April 2004.
21. Breen MS, Butts K, **Chen L**, Wilson DL. Image-guided Laser Thermal Ablation Therapy: A Comparison of Modeled Tissue Damage Using Interventional MR Temperature Images with Tissue Response. The International Society for Optical Engineering (SPIE) 2004 International Symposium on Medical Imaging, San Diego, California, February 14-19, 2004. *Proceedings of SPIE Medical Imaging 2004: Visualization, Image-Guided Procedures, and Display*. May 2004. 5367:516-523.
22. Breen MS, Butts K, **Chen L**, Saidel GM, Wilson DL. MRI-guided laser thermal ablation: model to predict cell death from MR thermometry images for real-time therapy monitoring. *Conf Proc IEEE Eng Med Biol Soc*. 2004;2:1028-31.
23. Breen MS, Butts K, **Chen L**, Saidel GM, Wilson DL. MRI-guided Laser Thermal Ablation: Model and Parameter Estimates Relating MR Thermometry Images to Cell Death. *Proceedings of IEEE International Symposium on Biomedical Imaging: From Nano to Macro*. Arlington, Virginia, April 2004.
24. **Chen L**, Konski A, Chen Z, Price R, Li J, Wang L, Qin L, Ma C. MRI study of tumor motion for radiation treatment planning. *Proc. Medical Physics*, 31(6), 1904, 2004.
25. **Chen L**, Chen Z, Price R, Li J, Wang L, Qin L, Ma C. Treatment setup for MRI-based treatment planning for prostate IMRT. *Proc. Medical Physics*, 31(6), 1925, 2004.
26. Wang L, Feigenberg S, Paskalev K, **Chen L**, Qin L, Ma C, Movsas B. Optimal treatment planning of extracranial stereotactic conformal radiotherapy for medically inoperable lung cancer. *ASTRO 2004*.
27. Wang L, Ma C, Paskalev K, Jacob R, **Chen L**, Feigenberg S, Movsas B. Feasibility study for clinical implementation of dose hypofractionation with IMRT for prostate cancer. *Proc. Medical Physics*, 31(6), 1788, 2004.

Lili Chen, Ph.D.

28. Qin L, Xiong W, Yang J, Li J, McNeeley S, **Chen L**, Price R, Ma C. Investigation of an electron specific multileaf collimator for modulated electron radiation therapy. Proc. Medical Physics, 31(6), 1798, 2004. Proc. Medical Physics, 31(6), 1798, 2004.
29. Li J, Wang L, **Chen L**, Yang J, Ma C. Monte carlo dose verification for IMRT plan delivered using micromultileaf collimators. Proc. Medical Physics, 31(6), 1844, 2004.
30. Qin L, Yang J, Li J, **Chen L**, Proce R, Ma C. Effect of voxel size on monte carlo dose calculations. Proc. Medical Physics, 31(6), 1883, 2004.
31. Chen Z, Ma C, Paskalev K, Richardson T, Palacio L and **Chen L**. Image distortion corrections for MRI based treatment planning. Proc. Medical Physics, 31(6), 1890, 2004.
32. Ma C, Xiong W, Yang J, Price R, **Chen L**, Pollack A. Image guided therapy: Aiming at clonogenic cells or hypoxic cells? Proc. Medical Physics, 31(6), 1890, 2004.
33. Chen Z, Ma C, Palacio L, Richardson T, Paskalev K and **Chen L**. Investigation of CT-MRI image intensity correlation for MRI-based dose calculation. Proc. Medical Physics, 31(6), 1897, 2004.

Funding applied for based on work resulting from or supported in part by this grant:

- PI, DOD Idea Development Award: **Funded**, PC073127, 2008-2011 (\$641, 250.00)
Proposal Title: MR Guided Pulsed High Intensity Focused Ultrasound Enhancement of Gene Therapy Combined with Androgen Deprivation and Radiotherapy for Prostate Cancer Treatment (2008-2011)
- PI, Focused Ultrasound Surgery Foundation (FUSF): Research award, **Funded** (\$102,970.00)
Proposal Title: MR Guided Pulsed High Intensity Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy for Prostate Cancer Treatment (2008)
- PI, Fox Cancer Center Seed Grant: **pending**
Proposal Title: MR Guided High-Intensity Focused Ultrasound for Enhancement of Chemo-Radiotherapy of Prostate Cancer

Conclusions

We have successfully performed the tasks scheduled in the “Statement of Work”. We have confirmed that treatment planning dose calculations using MRI-derived homogenous geometry are adequate for patient sizes within 38 cm after MR image distortion is corrected using the GDC software. We have investigated the effect of MRI residual distortion after GDC on IMRT treatment planning and dosimetry accuracy. We have evaluated MRI- and CT-based IMRT treatment optimization for plan consistency. We have validated the dosimetry accuracy of MRI-based treatment planning by recomputing MRI-based IMRT plans using patient CT data and an IMRT QA phantom. We have developed a point-by-point distortion correction technique to correct the residual MRI distortions after the GDC. We have performed Monte Carlo dose calculations using MRI-derived homogenous geometry with heterogeneity corrections. We have developed a practical method of dose calculation for MR-based treatment planning in heterogeneous patient anatomy. We have developed a practical technique to create MR-based DRRs for prostate IMRT that can be used for patient setup when MR-based treatment planning is applied clinically. We have developed guidelines for MRI-based treatment planning dose calculation and quality assurance programs for MRI simulation for prostate cancer treatment. We have successfully implemented MR imaging based treatment planning clinically at FCCC.

Note on Human Subject Protection Approval

We have an approved IRB (IRB# 04-848) by both Fox Chase Cancer Center and DOD for this project.

References

Chen L, Price RA Jr., Wang L, Li JS, Qin L, Ding M, Palacio E, T-B Nguyen, Ma C-M, Pollack A. Dosimetric evaluation of MRI-based treatment planning for prostate cancer. *Phys. Med. Biol.* 49: 5157-5170 (2004a).

Chen L, Price RA Jr., Wang L, Li JS, Qin L, Shawn M, Ma C-M, Freedman GM and Pollack A . MRI-Based Treatment Planning for Radiotherapy: Dosimetric Verification for Prostate IMRT. *International Journal of Radiation Oncology Biology Physics* 60(2): 636-47 (2004b).

Chen Z, Ma C-M, Paskalev K, Li J, Yang J, Richardson T, Palacio L, Xu X and Chen L. Investigation of MR Image Distortion for Radiotherapy Treatment Planning of Prostate Cancer. *Phys. Med. Biol* 51 1393-1403 (2006).

Chen Z, Ma C-M, Yang J, Li J, Luo W, Fan J, Paskalev KA, A. Price Jr A Chen Y and Chen L, Monte Carlo dose verification of MR image based IMRT treatment planning for prostate cancer, Proc. of the 15th International Conference on the Use of Computer in Radiation Therapy (ICCR), Eds: Jean-Pierre Bissonnette (Novel Digital Publishing, Oakville), 2007a, Volume II: 267-71.

Chen L, Nguyen T-B, Jones E, Chen Z, Luo W, Wang L, Price RA, Pollack A and Ma C-M. MRI-Based Treatment Planning for Prostate IMRT: Creation of Digitally Reconstructed Radiographs (DRR). *International Journal of Radiation Oncology Biology Physics* 68(3): 903-11 (2007).

Wang L, Movsas B, Jacob R, Fourkal E, Chen L, Price R, Feigenberg S, Konski A, Pollack A and Ma C. Stereotactic IMRT for prostate cancer: Dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT. *Journal of Applied Clinical Medical Physics* 5: 29-41 (2004a).

Wang L, R Jacob, Chen L, Feigenberg S, Konski A, Ma C and B Movsas. Stereotactic IMRT for prostate cancer: Setup accuracy of a new stereotactic body localization system. *Journal of Applied Clinical Medical Physics* 5: 18-28 (2004b).

Ma C-M, Li J S, Pawlicki T, Jiang S.B, Deng J, A Monte Carlo dose calculation tool for radiotherapy treatment planning, *Med. Phys.* 47:1671-89 (2002).

Jiang S B, Boyer A L, and Ma C-M 2001 Modeling the extrafocal radiation and monitor chamber backscatter for photon beam dose calculation *Med. Phys.* 28, 55-66.

Jiang S B, Deng J, Li J S, Pawlicki T, Boyer A L, and Ma C-M 2000 Modeling and commissioning of clinical photon beams for Monte Carlo treatment planning *XIII ICCR 2000* ed W Schlegel and T Bortfeld pp 434-6.

Lili Chen, Ph.D.

Yang J, Li J, Chen, L, Price RA, McNeeley S, Qin L, Wang, L, Xiong W and Ma C-M. Monte Carlo evaluation of heterogeneity effect in IMRT treatment planning for prostate cancer *Phys. Med. Biol.* 50: 1-10 (2005).

Li J S, Pawlicki T, Deng J, Jiang S B and Ma C-M 2000 Validation of a Monte Carlo dose calculation tool for radiotherapy treatment planning *Phys. Med. Biol.* 45 2969-85.

Ma C-M, Mok E, Kapur A, Findley D, Brain S, Forster K and Boyer A L. Clinical implementation of a Monte Carlo treatment planning system, *Med. Phys.* 26:2133-43 (1999).

Chen L, Zhu J, Xu X, Wang L, Paskalev K, Chen Z, Movsas B, and Ma C. Image Guided Radiation Therapy: Investigation of Interfraction Setup and External Contour Variation for Prostate IMRT Using CT and MRI *Phys. Med.* Vol. 32 1928 (2005).

Lee YK and Bollet M, 2003 Radiation Treatment Planning of Prostate Cancer Using Magnetic Resonance Imaging Alone, *Radiotherapy and Oncology* 66:203-216.

List of Key Personnel

Lili Chen, Ph.D. - Associate Member
Zuoqun Chen- Postdoctoral Associate
Shawn McNeeley, M.S. - Physicist